A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Of Efficacy And Safety Of Enzalutamide In Combination With Exemestane In Patients With Advanced Breast Cancer That Is Estrogen Or Progesterone Receptor-positive And Her2-normal
Latest Information Update: 02 May 2024
At a glance
- Drugs Enzalutamide (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 22 Apr 2024 Planned End Date changed from 31 Dec 2023 to 28 Jun 2024.
- 25 Apr 2023 Planned End Date changed from 31 Mar 2023 to 31 Dec 2023.
- 18 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Mar 2023.